

U.S. Serial No. 10/608,604

Atty Docket No. R0125C-CON

77. (previously added) The compound of Claim 76, wherein R⁵ is (C₁₋₆)alkyl, and R⁶ is hydrogen or (C₁₋₆)alkyl.

78. (previously added) The compound of Claim 76, wherein R¹ is ethyl or propyl.

79. (previously added) The compound of Claim 78, wherein R² is -OR', and R³ is -OR' or hydrogen.

80. (previously added) The compound of Claim 46, comprising:

(4-[(R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl]-propyl-amino]-piperidin-1-yl)-piperazin-1-yl-methanone;

(4-[(R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl]-propyl-amino)-piperidin-1-yl)-morpholin-4-yl-methanone;

(4-[(R)-6,7-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl]-propyl-amino)-piperidin-1-yl)-piperidin-4-yl-methanone;

1-(4-[(R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl]-propyl-amino)-piperidin-1-yl)-ethanone;

(4-[(R)-6,7-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl]-propyl-amino)-piperidin-1-yl)-piperazin-1-yl-methanone;

(4-[(R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl]-propyl-amino)-piperidin-1-yl)-(4-methyl-piperazin-1-yl)-methanone; and

(4-[(R)-7-Bromo-1,2,3,4-tetrahydro-naphthalen-2-yl]-propyl-amino)-piperidin-1-yl)-piperidin-4-yl-methanone.

81. (previously added) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 46 in admixture with an acceptable carrier.

82. (previously added) The pharmaceutical composition of Claim 81, wherein the compound is suitable for administration to a subject having a disease state which is alleviated by treatment with a M2/M3 muscarinic receptor antagonist.

83. (previously added) A method of treating a subject which comprises administering to the subject with a disease treatable with a M2/M3 muscarinic receptor antagonist a therapeutically effective amount of one or more compounds of Claim 46, wherein the disease is selected from the

group consisting of overactive bladder - - - - -
allergies or asthma.

BUCKWALB:123609v2

-5-

U.S. Serial No. 10/608,604

Atty-Docket No. R0125C-CON

84. (previously added) The method of Claim 83, wherein the disease state is associated with smooth muscle disorders comprising diseases of the genitourinary or gastrointestinal tract, or of respiratory states.

85. (previously added) The method of Claim 84, wherein the disease state is associated with the genitourinary tract.

86. (previously added) *gmet in claim 83, wherein*
The method of Claim 85, wherein the disease state comprises overactive bladder, detrusor hyperactivity, urgency, frequency, reduced bladder capacity, incontinence episodes, changes in bladder capacity, micturition threshold, unstable bladder contractions, sphincteric spasticity, outlet obstruction, outlet insufficiency, pelvic hypersensitivity, idiopathy conditions, ~~or~~ detrusor instability.

87. (previously added) The method of treatment of Claim 84, wherein the disease state comprises respiratory states.

88. (previously added) The method of treatment of Claim 87, wherein the disease state comprises respiratory states from allergies or asthma.

89. (previously added) The method of treatment of Claim 84, wherein the disease state comprises gastrointestinal tract disorders.